Clinical Trials


Home Clinical Trials Investigational drug trial for Neuromyelitis Optica


Now enrolling...The use of an investigational drug (SA237) for Neuromyelitis Optica (NMO)

Posted March 17, 2016 by

DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

 

To qualify, patients must:

Þ Age 18 to 74, inclusive at time of informed consent

Þ Pts must be diagnosed with NMO or NMOSD (by definition)

Þ Clinical evidence of at least 1 documented relapse within 12 months

Þ EDSS score from 0 to 6.5 at screening

 

For more information, please contact Jeneane Henry, RN BSN, Clinical Research Nurse at 804-828-7802 or jeneane.henry@vcuhealth.org

 

Investigators:

Warren L. Felton III, MD (Principal Investigator), Dept. of Neurology at VCU

Unsong Oh, MD (Sub-Investigator), Dept. of Neurology at VCU

 

Clinical Research Nurse / Study Coordinator:

Jeneane Henry, RN BSN, Dept. of Neurology at VCU